№ files_lp_4_process_3_134382
File format: docx
Character count: 1430
File size: 15 KB
Collection of standardized text messages intended for sending to patients with Asthma or COPD, including separate messages for parents of children with Asthma, with links to relevant health apps.
Year:
2026
Region:
West Yorkshire, UK
Subject:
Health communication / Patient engagement
Document type:
Template messages
Organization:
West Yorkshire Health Service
Target audience:
Patients with Asthma or COPD, parents/carers of children with Asthma
Platforms referenced:
Google Play, Apple App Store
Conditions addressed:
Asthma, COPD
Message length:
Short (≤160 characters), Long (≤300 characters)
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / City:
Global
Topic:
Chronic Obstructive Pulmonary Disease (COPD) Management
Document Type:
Research Study
Organization / Institution:
Various international medical organizations
Authors:
Schrijver J, Lenferink A, Brusse-Keizer M, et al.
Target Audience:
Healthcare professionals, researchers, policymakers
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2023
Region / city:
Australia
Type of document:
Pharmaceutical submission / Public Summary Document
Regulatory authority:
Therapeutic Goods Administration (TGA)
Submitted by:
Generic Health Pty Ltd
Product:
Tiotropium Lupin 18 microgram powder for inhalation, LupinHaler device
Indication:
Chronic obstructive pulmonary disease (COPD)
Previous PBS listing:
Spiriva 18 microgram powder for inhalation, HandiHaler device
Submission type:
Category 4 (cost-minimisation comparison)
PBS item code:
8626BMP,NP
Maximum quantity:
1 pack, 30 units
Prescriber type:
Nurse Practitioners, Medical Practitioners
Restriction type:
Restricted benefit
Administrative advice:
Not to be used in combination with LAMA/LABA or SAMA; adherence to current inhaler technique to be reviewed at each clinical visit; diagnosis requires spirometry confirmation
Year:
2023
Region / City:
England
Topic:
Healthcare, Quality Standards
Document Type:
Policy document
Organization / Institution:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Target Audience:
Healthcare providers, Medical professionals
Period of Validity:
2023-2024
Approval Date:
01/04/2023
Date of Amendments:
01/08/2023
Contextual Description:
Policy document outlining business rules for COPD management under the Quality and Outcomes Framework for NHS England.
Year:
2019
Region / City:
United Kingdom
Topic:
Chronic Obstructive Pulmonary Disease (COPD), Oxygen Saturation
Document Type:
Guidance
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
NICE
Target Audience:
General practitioners, healthcare professionals
Period of Validity:
Not specified
Approval Date:
August 2019
Date of Last Update:
N/A
Year:
Not specified
Region / City:
Not specified
Topic:
COPD, Medical Research Council score, Fibrinogen levels, Six-minute walking test, Medication costs, Probabilistic analysis
Document Type:
Scientific Analysis
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Healthcare professionals, Clinicians
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Country:
China
Ethics Approval Number:
2023KYLL014
Scientific Field:
Genetic epidemiology
Research Topic:
Causal relationship between chronic obstructive pulmonary disease and lung adenocarcinoma
Study Design:
Two-sample Mendelian randomization study
Document Type:
Reporting checklist
Exposure:
Chronic obstructive pulmonary disease (COPD)
Outcome:
Lung adenocarcinoma (LUAD)
Data Sources:
GWAS dataset ebi-a-GCST90018807; GWAS dataset ebi-a-GCST004744; TCGA; GEO datasets GSE116959 and GSE76925
Sample Size:
57 LUAD patients, 11 healthy controls, 111 COPD cases, 40 smoking controls
Key Biomarkers:
FCRLA, GREM1, MMP9
Statistical Methods:
Inverse variance weighting (IVW), MR Egger, MR-PRESSO, LASSO regression, false discovery rate correction
Software:
R version 4.2.1; TwoSampleMR package; ggplot2
Diagnostic Criteria:
COPD defined by spirometry (FEV1/FVC < 0.7); LUAD confirmed by histopathology
Genetic Variant Selection Criteria:
Genome-wide significance threshold p < 5 × 10⁻⁸; LD pruning r² < 0.01
Core Mendelian Randomization Assumptions:
Relevance, independence, exclusion restriction
Document type:
Clinical correspondence letter
Medical topic:
COPD and bronchiectasis management
Medication:
Azithromycin
Purpose:
Recommendation to initiate azithromycin therapy to reduce exacerbations
Sender role:
Respiratory specialist
Recipient role:
General Practitioner
Patient category:
Patients with COPD or bronchiectasis experiencing exacerbations
Clinical objective:
Reduction in number of exacerbations within a 12-month period
Review schedule:
6 months after treatment initiation and additional follow-up months as specified
Prescribing status:
Amber Recommended
Prescribing guidance source:
Pan-Mersey Area Prescribing Committee
Response requirement:
GP confirmation or refusal within 14 days
Sections included:
Treatment dose and frequency, indication, review plan, GP decision section
Year:
2010
Organization:
Key Medical Resources, Inc.
Author:
Terry Rudd, RN, MSN
Type of Document:
Educational self-study module
Target Audience:
Nurses and healthcare professionals
Location:
Rancho Cucamonga, California, USA
Continuing Education Hours:
15.0
Certification:
California Board of Registered Nursing CEP#15122
Format:
Self-study with exam and evaluation form
Content Focus:
Asthma, COPD, respiratory assessment, lung function, pharmacology
Year:
2021
Study:
Global Burden of Disease Study 2021 (GBD 2021)
Topic:
Epidemiological modeling and data sources for COPD incidence and mortality
Document type:
Technical nomenclature and methodological description
Field:
Epidemiology and public health
Model:
Age–Period–Cohort (APC) model
Data source system:
Global Health Data Exchange (GHDx)
Database:
Causes of Death (CoD) database
Modeling tools:
DisMod-MR; MR-BRT (Bayesian regularized model with temporal smoothing)
Geographic coverage:
204 countries and territories
Health condition:
Chronic Obstructive Pulmonary Disease (COPD)
Data source types:
surveys, censuses, vital registration, surveillance systems, cancer registries, police records, sibling history, survey/census data, minimally invasive tissue sample diagnoses
Reference parameters:
reference age group (a0), reference period (p0), reference cohort (c0)
Statistical measures:
Net Drift, Age Deviations, Period Deviations, Cohort Deviations, Longitudinal Age Curve, Period Rate Ratios, Cohort Rate Ratios, Local Drifts
Data access platform:
Global Health Data Exchange citation tool
File format available:
CSV metadata export
Outlier criteria:
exclusion of implausible values, conflicts with age or temporal patterns, and inconsistencies with comparable data sources
Year:
2026
Region / City:
Multicenter, unspecified locations
Topic:
Chronic Obstructive Pulmonary Disease
Document Type:
Clinical Study Supplement
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Clinical researchers and healthcare professionals
Study Phase:
Not specified
Inclusion Criteria:
Adults aged 40–80 with COPD, stable maintenance therapy, capable of performing spirometry and following study procedures
Exclusion Criteria:
Recent severe infections or surgeries, significant comorbidities, prohibited medication use, pregnancy or breastfeeding, recent participation in other trials
Prohibited Medications:
Systemic or inhaled corticosteroids, certain antibiotics, leukotriene inhibitors, theophylline, PDE4 inhibitors, terbutaline, nebulized COPD medications, oral β2-agonists
Study Visits:
Screening (visit 1), baseline and dosing (visit 2), mid-study assessment (visit 3), end-of-treatment assessment (visit 4), follow-up call post-treatment
Assessment Tools:
CAT, mMRC Dyspnea Scale, spirometry, vital signs, physical examination
Treatment Duration:
12 weeks
Compliance Monitoring:
Dispensed medication retrieval and assessment at visits 3 and 4
Year:
2010–2011
Region:
United Kingdom, England
Subject:
Telehealth, Chronic Obstructive Pulmonary Disease (COPD), Health Economics
Document type:
Research Study / Pilot Programme Report
Organization:
National Health Service Direct (NHSD)
Authors:
Not specified
Target population:
Patients with chronic obstructive pulmonary disease (COPD)
Study sites:
Two Primary Care Trusts (PCT1, PCT2)
Participants:
321 enrolled, 227 included in final analysis
Intervention:
Remote patient monitoring / telehealth
Outcome measures:
Cost-effectiveness, resource utilization, hospital admissions, length of stay
Data collection period:
12 months before, immediately before, and during monitoring
Keywords:
telehealth, telemedicine, cost-effectiveness, remote patient monitoring
Year:
2018
Region / city:
Regional Victoria
Topic:
Pathophysiology, Pharmacology, COPD, Pneumonia
Document type:
Case report
Organization / institution:
CRICOS Provider No. 00103D
Author:
Not specified
Target audience:
Healthcare professionals, Medical students
Action period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Note:
Year
Topic:
Asthma Management
Document Type:
Healthcare Plan
Year:
2020
Region / City:
New Zealand
Topic:
Health assessment for police recruitment
Document Type:
Medical Questionnaire
Institution:
New Zealand Police
Author:
New Zealand Police
Target Audience:
Applicants for New Zealand Police recruitment
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
New Zealand
Topic:
Health assessment for police recruitment
Document Type:
Questionnaire
Organization:
New Zealand Police
Author:
New Zealand Police
Target Audience:
Applicants for New Zealand Police recruitment
Effective Period:
Until completion of the medical review
Approval Date:
2023
Date of Changes:
N/A
Note:
Year
Year:
2023
Region / City:
New Zealand
Topic:
Health assessment for recruitment
Document type:
Medical questionnaire
Organization / Institution:
New Zealand Police
Author:
Not specified
Target audience:
Recruitment applicants
Validity period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2021
Region / city:
West Yorkshire
Theme:
Asthma Management
Document type:
Guideline
Organization:
British Thoracic Society, National Institute for Health and Care Excellence (NICE), Global Initiative for Asthma (GINA)
Author:
Not specified
Target audience:
Healthcare professionals
Effective period:
Ongoing
Approval date:
Not specified
Revision date:
Not specified
Year:
2024
Region / city:
Canberra, ACT
Theme:
Asthma, Paediatrics, Clinical Guidelines
Document Type:
Clinical Guideline
Organization / institution:
Canberra Health Services
Author:
Paediatric Improvement Collaborative (PIC)
Target Audience:
Healthcare professionals, Paediatricians, Clinical staff
Effective period:
Indefinite
Approval date:
21/11/2024
Amendment date:
21/11/2024
Superseded document:
CHS21/253 Acute Asthma - Paediatrics (infants, children and adolescents)
Acknowledgment:
Ngunnawal people as traditional custodians of the ACT
Context:
Clinical guideline for the assessment and management of paediatric asthma within the Canberra Health Services Network.
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.